NANJING, China, Aug. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced a strategic partnership with Sun Yat-Sen University Cancer Center.
Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.
Through the strategic partnership, Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center will cooperate on researching and developing innovative anti-cancer drugs, as well as conducting a joint training program to develop personnel in advanced R&D.
"We are delighted to enter into a strategic partnership with Sun Yat-Sen University Cancer Center, one of China's outstanding cancer research institutions," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "I am confident that this cooperation will enhance Simcere's R&D capabilities and contribute to the future development of innovative cancer drugs in China."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
CONTACT: investor and media contacts, ir@simcere.com; or Frank Zhao, Chief
Financial Officer of Simcere Pharmaceutical Group in Nanjing,
+86-25-8556-6666 x8818; or Kate Tellier, of Brunswick Group LLC in the
United States, +1-212-333-3810; or Ruirui Jiang, of Brunswick Group in
Beijing, +86-10-6566-2256; or Joseph Lo Chi-Lun, of Brunswick Group in Hong
Kong, +852-3512-500
Web site: http://simcere.com/
